PL2892507T3 - Powlekana kompozycja farmaceutyczna zawierająca regorafenib - Google Patents

Powlekana kompozycja farmaceutyczna zawierająca regorafenib

Info

Publication number: PL2892507T3
Authority: PL; Poland
Prior art keywords: pharmaceutical composition; composition containing; coated pharmaceutical; containing regorafenib; regorafenib
Prior art date: 2012-09-06

Application number

PL13762967T

Other languages

English (en)

Inventor

Susanne Skrabs

Adrian Funke

Mayk Kresse

Ulrich Oberdieck

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-06

Filing date

2013-09-05

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2892507(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-05 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2017-09-29 Publication of PL2892507T3 publication Critical patent/PL2892507T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL13762967T 2012-09-06 2013-09-05 Powlekana kompozycja farmaceutyczna zawierająca regorafenib PL2892507T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12183331		2012-09-06

Publications (1)

Publication Number	Publication Date
PL2892507T3 true PL2892507T3 (pl)	2017-09-29

Family

ID=46963450

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13762967T PL2892507T3 (pl)	2012-09-06	2013-09-05	Powlekana kompozycja farmaceutyczna zawierająca regorafenib

Country Status (43)

Country	Link
US (1)	US20140065212A1 (pl)
EP (2)	EP2892507B1 (pl)
JP (1)	JP6445436B2 (pl)
KR (1)	KR102162036B1 (pl)
CN (5)	CN111249247A (pl)
AP (1)	AP2015008292A0 (pl)
AR (1)	AR092439A1 (pl)
AU (1)	AU2013312531B2 (pl)
BR (1)	BR112015004936B1 (pl)
CA (1)	CA2883767C (pl)
CL (1)	CL2015000544A1 (pl)
CO (1)	CO7310528A2 (pl)
CR (1)	CR20150114A (pl)
CU (1)	CU24244B1 (pl)
CY (1)	CY1118839T1 (pl)
DK (1)	DK2892507T3 (pl)
EA (1)	EA027685B1 (pl)
ES (1)	ES2623205T3 (pl)
GT (1)	GT201500053A (pl)
HK (1)	HK1214170A1 (pl)
HR (1)	HRP20170620T1 (pl)
HU (1)	HUE032758T2 (pl)
IL (1)	IL237350B (pl)
IN (1)	IN2015DN01673A (pl)
JO (1)	JO3479B1 (pl)
LT (1)	LT2892507T (pl)
MA (1)	MA37888B1 (pl)
MX (1)	MX359922B (pl)
MY (1)	MY176135A (pl)
NZ (1)	NZ705578A (pl)
PE (1)	PE20151005A1 (pl)
PH (1)	PH12015500460A1 (pl)
PL (1)	PL2892507T3 (pl)
PT (1)	PT2892507T (pl)
RS (1)	RS56019B1 (pl)
SA (1)	SA515360113B1 (pl)
SG (1)	SG11201501683WA (pl)
SI (1)	SI2892507T1 (pl)
TW (1)	TWI640329B (pl)
UA (1)	UA115994C2 (pl)
UY (1)	UY35006A (pl)
WO (1)	WO2014039677A1 (pl)
ZA (1)	ZA201501394B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20160220494A1 (en) *	2013-09-13	2016-08-04	Bayer Pharma Aktiengesellschaft	Pharmaceutical compositions containing refametinib
CN104586808B (zh) *	2014-12-27	2017-08-18	北京元延医药科技股份有限公司	抗肿瘤药物组合物
CN105267167A (zh) *	2015-09-11	2016-01-27	江苏嘉逸医药有限公司	一种瑞戈非尼口服固体药物组合物的制备方法
CN105136956A (zh) *	2015-09-11	2015-12-09	江苏嘉逸医药有限公司	一种快速测定瑞戈非尼含量的方法
CN106880615A (zh) *	2015-12-15	2017-06-23	北大方正集团有限公司	一种瑞戈非尼的口服固体制剂及其制备方法
CN106880607A (zh) *	2015-12-15	2017-06-23	北大方正集团有限公司	一种含有瑞戈非尼的口腔崩解片及其制备方法
CN105496975B (zh) *	2015-12-17	2019-01-04	河南润弘制药股份有限公司	一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) *	2015-12-28	2017-07-04	江苏先声药业有限公司	一种瑞戈非尼速释微丸及其制备方法
CN105879049B (zh) *	2016-05-13	2019-03-26	浙江大学	一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) *	2016-07-27	2018-02-06	江苏先声药业有限公司	一种瑞戈非尼固体分散体及其制备方法
KR102673422B1 (ko) *	2017-06-02	2024-06-07	바이엘 헬쓰케어 엘엘씨	암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합
EA202190217A1 (ru) *	2018-07-06	2021-04-16	Аджиос Фармасьютикалз, Инк.	Формы ивосидениба и фармацевтические композиции
CN111053751A (zh) *	2018-10-16	2020-04-24	正大天晴药业集团股份有限公司	瑞戈非尼的缓释片剂及其制备方法
TWI799599B (zh) *	2019-06-06	2023-04-21	華納國際生物科技股份有限公司	醫藥或保健品自乳化固體分散組成物
EP3861989A1 (en) *	2020-02-07	2021-08-11	Bayer Aktiengesellschaft	Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112587485A (zh) *	2021-01-08	2021-04-02	湖南南新制药股份有限公司	一种药物固体分散体及其制备方法
CN113018274A (zh) *	2021-03-10	2021-06-25	药源生物科技（启东）有限公司	一种含羟丙甲纤维素的药物组合物及其制备方法
WO2024191389A1 (en) *	2023-03-10	2024-09-19	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	A pharmaceutical composition of regorafenib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20120034211A (ko) *	2002-09-20	2012-04-10	안드렉스 랩스 엘엘씨	약제학적 정제
CN1265793C (zh) *	2002-11-18	2006-07-26	杭州容立医药科技有限公司	左西替利嗪伪麻黄碱复方口服制剂及制备方法
EP1663978B1 (en)	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP2009519266A (ja) *	2005-12-15	2009-05-14	バイエル・ヘルスケア・アクチェンゲゼルシャフト	炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア類
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) *	2006-10-13	2008-04-17	Pfizer Products Inc.	Pharmaceutical formulation tablet
EA200970552A1 (ru) *	2006-12-07	2009-10-30	Эли Лилли Энд Компани	Изделие с празугрелом
JP5351490B2 (ja) *	2007-10-25	2013-11-27	バイエル薬品株式会社	ニフェジピン含有有核錠剤およびその製法
AR081060A1 (es) *	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2012260605B2 (en) *	2011-05-20	2015-02-19	Astrazeneca Uk Limited	Pharmaceutical composition of rosuvastatin calcium

2013
- 2013-09-04 UY UY0001035006A patent/UY35006A/es active IP Right Grant
- 2013-09-04 JO JOP/2013/0268A patent/JO3479B1/ar active
- 2013-09-04 AR ARP130103145A patent/AR092439A1/es not_active Application Discontinuation
- 2013-09-05 EA EA201590520A patent/EA027685B1/ru not_active IP Right Cessation
- 2013-09-05 CN CN202010052300.XA patent/CN111249247A/zh active Pending
- 2013-09-05 SG SG11201501683WA patent/SG11201501683WA/en unknown
- 2013-09-05 MX MX2015002815A patent/MX359922B/es active IP Right Grant
- 2013-09-05 PE PE2015000289A patent/PE20151005A1/es active IP Right Grant
- 2013-09-05 TW TW102131928A patent/TWI640329B/zh active
- 2013-09-05 CN CN201380049461.1A patent/CN104902878A/zh active Pending
- 2013-09-05 NZ NZ705578A patent/NZ705578A/en unknown
- 2013-09-05 CU CUP2015000020A patent/CU24244B1/es unknown
- 2013-09-05 LT LTEP13762967.1T patent/LT2892507T/lt unknown
- 2013-09-05 ES ES13762967.1T patent/ES2623205T3/es active Active
- 2013-09-05 HU HUE13762967A patent/HUE032758T2/en unknown
- 2013-09-05 CN CN202310410047.4A patent/CN116392485A/zh active Pending
- 2013-09-05 RS RS20170400A patent/RS56019B1/sr unknown
- 2013-09-05 SI SI201330621T patent/SI2892507T1/sl unknown
- 2013-09-05 AU AU2013312531A patent/AU2013312531B2/en active Active
- 2013-09-05 AP AP2015008292A patent/AP2015008292A0/xx unknown
- 2013-09-05 CN CN202310406916.6A patent/CN116392598A/zh active Pending
- 2013-09-05 KR KR1020157008402A patent/KR102162036B1/ko active IP Right Grant
- 2013-09-05 EP EP13762967.1A patent/EP2892507B1/en active Active
- 2013-09-05 BR BR112015004936-2A patent/BR112015004936B1/pt active IP Right Grant
- 2013-09-05 MY MYPI2015700672A patent/MY176135A/en unknown
- 2013-09-05 PT PT137629671T patent/PT2892507T/pt unknown
- 2013-09-05 JP JP2015531194A patent/JP6445436B2/ja active Active
- 2013-09-05 WO PCT/US2013/058257 patent/WO2014039677A1/en active Application Filing
- 2013-09-05 IN IN1673DEN2015 patent/IN2015DN01673A/en unknown
- 2013-09-05 US US14/018,516 patent/US20140065212A1/en not_active Abandoned
- 2013-09-05 UA UAA201502818A patent/UA115994C2/uk unknown
- 2013-09-05 CN CN202310409897.2A patent/CN116392484A/zh active Pending
- 2013-09-05 DK DK13762967.1T patent/DK2892507T3/en active
- 2013-09-05 EP EP17153541.2A patent/EP3243508A1/en not_active Withdrawn
- 2013-09-05 PL PL13762967T patent/PL2892507T3/pl unknown
- 2013-09-05 MA MA37888A patent/MA37888B1/fr unknown
- 2013-09-05 CA CA2883767A patent/CA2883767C/en active Active
2015
- 2015-02-22 IL IL237350A patent/IL237350B/en active IP Right Grant
- 2015-03-02 ZA ZA2015/01394A patent/ZA201501394B/en unknown
- 2015-03-03 PH PH12015500460A patent/PH12015500460A1/en unknown
- 2015-03-04 SA SA515360113A patent/SA515360113B1/ar unknown
- 2015-03-05 GT GT201500053A patent/GT201500053A/es unknown
- 2015-03-05 CR CR20150114A patent/CR20150114A/es unknown
- 2015-03-05 CL CL2015000544A patent/CL2015000544A1/es unknown
- 2015-03-05 CO CO15050805A patent/CO7310528A2/es unknown
2016
- 2016-03-01 HK HK16102327.2A patent/HK1214170A1/zh unknown
2017
- 2017-04-19 HR HRP20170620TT patent/HRP20170620T1/hr unknown
- 2017-04-21 CY CY20171100450T patent/CY1118839T1/el unknown

Also Published As

Publication number	Publication date
IN2015DN01673A (pl)	2015-07-03
PE20151005A1 (es)	2015-06-27
EP3243508A1 (en)	2017-11-15
HRP20170620T1 (hr)	2017-06-30
CU20150020A7 (es)	2015-05-28
CY1118839T1 (el)	2018-01-10
MA37888B1 (fr)	2019-08-30
KR20150048872A (ko)	2015-05-07
CA2883767A1 (en)	2014-03-13
CN116392485A (zh)	2023-07-07
GT201500053A (es)	2015-10-12
HK1214170A1 (zh)	2016-07-22
JP2015527395A (ja)	2015-09-17
AR092439A1 (es)	2015-04-22
PH12015500460B1 (en)	2015-04-20
SA515360113B1 (ar)	2016-08-10
EP2892507B1 (en)	2017-02-01
CR20150114A (es)	2015-05-11
CL2015000544A1 (es)	2015-08-21
UY35006A (es)	2014-03-31
SI2892507T1 (sl)	2017-08-31
CN104902878A (zh)	2015-09-09
MX359922B (es)	2018-10-16
SG11201501683WA (en)	2015-04-29
WO2014039677A1 (en)	2014-03-13
AP2015008292A0 (en)	2015-02-28
UA115994C2 (uk)	2018-01-25
MX2015002815A (es)	2015-05-15
AU2013312531B2 (en)	2017-10-19
JP6445436B2 (ja)	2018-12-26
RS56019B1 (sr)	2017-09-29
PT2892507T (pt)	2017-05-02
LT2892507T (lt)	2017-06-12
TW201414510A (zh)	2014-04-16
ZA201501394B (en)	2016-07-27
CN111249247A (zh)	2020-06-09
TWI640329B (zh)	2018-11-11
PH12015500460A1 (en)	2015-04-20
NZ705578A (en)	2017-10-27
EP2892507A1 (en)	2015-07-15
CA2883767C (en)	2018-11-13
BR112015004936B1 (pt)	2022-12-06
CU24244B1 (es)	2017-02-02
IL237350A0 (en)	2015-04-30
AU2013312531A1 (en)	2015-03-12
MA37888A1 (fr)	2018-07-31
EA027685B1 (ru)	2017-08-31
EA201590520A1 (ru)	2015-10-30
HUE032758T2 (en)	2017-10-30
JO3479B1 (ar)	2020-07-05
MY176135A (en)	2020-07-24
BR112015004936A2 (pt)	2017-07-04
CO7310528A2 (es)	2015-06-30
IL237350B (en)	2020-11-30
CN116392484A (zh)	2023-07-07
DK2892507T3 (en)	2017-05-01
CN116392598A (zh)	2023-07-07
ES2623205T3 (es)	2017-07-10
US20140065212A1 (en)	2014-03-06
KR102162036B1 (ko)	2020-10-07

Publication	Publication Date	Title
HK1214170A1 (zh)	2016-07-22	含有瑞戈非尼的包衣的藥物組合物
ZA201501930B (en)	2016-01-27	Pharmaceutical composition
EP2832730A4 (en)	2015-09-09	MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1199821A1 (en)	2015-07-24	Oral pharmaceutical composition
SG11201405578TA (en)	2014-11-27	Pharmaceutical composition containing peptide
HK1199822A1 (zh)	2015-07-24	口服給藥用醫藥組合物
IL266415A (en)	2019-06-30	Innovative pharmaceutical composition
ZA201505196B (en)	2017-11-29	Topical ophthalmological pharmaceutical composition containing regorafenib
ZA201502987B (en)	2016-11-30	Pharmaceutical composition
SI2638894T1 (sl)	2017-01-31	Farmacevtski sestavek, ki vsebuje fosfolipid
EP2897590A4 (en)	2016-05-04	PHARMACEUTICAL COMPOSITION
ZA201400751B (en)	2014-12-25	Pharmaceutical composition
GB201221130D0 (en)	2013-01-09	New pharmaceutical composition
GB201207628D0 (en)	2012-06-13	New pharmaceutical composition
GB201207701D0 (en)	2012-06-13	New pharmaceutical composition
AU2012904295A0 (en)	2012-10-18	Pharmaceutical composition